Literature DB >> 23625984

Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis.

Marc Corbera-Bellalta1, Ana García-Martínez, Ester Lozano, Ester Planas-Rigol, Itziar Tavera-Bahillo, Marco A Alba, Sergio Prieto-González, Montserrat Butjosa, Georgina Espígol-Frigolé, José Hernández-Rodríguez, Pedro L Fernández, Pascale Roux-Lombard, Jean-Michel Dayer, Mahboob U Rahman, Maria C Cid.   

Abstract

BACKGROUND: Search for therapeutic targets in giant-cell arteritis (GCA) is hampered by the scarcity of functional systems. We developed a new model consisting of temporal artery culture in tri-dimensional matrix and assessed changes in biomarkers induced by glucocorticoid treatment.
METHODS: Temporal artery sections from 28 patients with GCA and 22 controls were cultured in Matrigel for 5 days in the presence or the absence of dexamethasone. Tissue mRNA concentrations of pro-inflammatory mediators and vascular remodelling molecules was assessed by real-time RT-PCR. Soluble molecules were measured in the supernatant fluid by immunoassay.
RESULTS: Histopathological features were exquisitely preserved in cultured arteries. mRNA concentrations of pro-inflammatory cytokines (particularly IL-1β and IFNγ), chemokines (CCL3/MIP-1α, CCL4/MIP-1β, CCL5/RANTES) and MMP-9 as well as IL-1β and MMP-9 protein concentrations in the supernatants were significantly higher in cultured arteries from patients compared with control arteries. The culture system itself upregulated expression of cytokines and vascular remodelling factors in control arteries. This minimised differences between patients and controls but underlines the relevance of changes observed. Dexamethasone downregulated pro-inflammatory mediator (IL-1β, IL-6, TNFα, IFNγ, MMP-9, TIMP-1, CCL3 and CXCL8) mRNAs but did not modify expression of vascular remodelling factors (platelet derived growth factor, MMP-2 and collagens I and III).
CONCLUSIONS: Differences in gene expression in temporal arteries from patients and controls are preserved during temporal artery culture in tri-dimensional matrix. Changes in biomarkers elicited by glucocorticoid treatment satisfactorily parallel results obtained in vivo. This may be a suitable model to explore pathogenetic pathways and to perform preclinical studies with new therapeutic agents.

Entities:  

Keywords:  Chemokines; Corticosteroids; Cytokines; Giant Cell Arteritis; Systemic vasculitis

Mesh:

Substances:

Year:  2013        PMID: 23625984     DOI: 10.1136/annrheumdis-2012-202883

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  15 in total

1.  Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis.

Authors:  Alicia Rodriguez-Pla; Roscoe L Warner; David Cuthbertson; Simon Carette; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Larry W Moreland; Christian Pagnoux; Philip Seo; Ulrich Specks; Antoine G Sreih; Steven R Ytterberg; Kent J Johnson; Peter A Merkel; Paul A Monach
Journal:  J Rheumatol       Date:  2019-09-01       Impact factor: 4.666

Review 2.  Biomarkers in vasculitis.

Authors:  Paul A Monach
Journal:  Curr Opin Rheumatol       Date:  2014-01       Impact factor: 5.006

Review 3.  Highlights in clinical medicine-Giant cell arteritis, polymyalgia rheumatica and Takayasu's arteritis: pathogenic links and therapeutic implications.

Authors:  Antonio Giovanni Solimando; Angelo Vacca; Franco Dammacco
Journal:  Clin Exp Med       Date:  2021-11-06       Impact factor: 5.057

4.  Hypoxia-stimulated cardiac fibroblast production of IL-6 promotes myocardial fibrosis via the TGF-β1 signaling pathway.

Authors:  Jia-Hong Wang; Lan Zhao; Xin Pan; Nan-Nan Chen; Jian Chen; Qun-Lin Gong; Feng Su; Jian Yan; Yan Zhang; Shao-Heng Zhang
Journal:  Lab Invest       Date:  2016-06-27       Impact factor: 5.662

Review 5.  Giant Cell Arteritis: Beyond Corticosteroids.

Authors:  Lauren Steel; Asad Khan; Bhaskar Dasgupta
Journal:  Drugs Aging       Date:  2015-08       Impact factor: 3.923

6.  Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients.

Authors:  Sergio Prieto-González; Nekane Terrades-García; Marc Corbera-Bellalta; Ester Planas-Rigol; Chie Miyabe; Marco A Alba; Ariel Ponce; Itziar Tavera-Bahillo; Giuseppe Murgia; Georgina Espígol-Frigolé; Javier Marco-Hernández; José Hernández-Rodríguez; Ana García-Martínez; Sebastian H Unizony; Maria C Cid
Journal:  RMD Open       Date:  2017-12-22

7.  Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways.

Authors:  Georgina Espígol-Frigolé; Ester Planas-Rigol; Ester Lozano; Marc Corbera-Bellalta; Nekane Terrades-García; Sergio Prieto-González; Ana García-Martínez; Jose Hernández-Rodríguez; Josep M Grau; Maria C Cid
Journal:  Front Immunol       Date:  2018-04-20       Impact factor: 7.561

Review 8.  Glucocorticoids-All-Rounders Tackling the Versatile Players of the Immune System.

Authors:  Cindy Strehl; Lisa Ehlers; Timo Gaber; Frank Buttgereit
Journal:  Front Immunol       Date:  2019-07-24       Impact factor: 7.561

Review 9.  FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC.

Authors:  Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-11       Impact factor: 9.236

10.  ROS-producing immature neutrophils in giant cell arteritis are linked to vascular pathologies.

Authors:  Lihui Wang; Zhichao Ai; Tariq Khoyratty; Kristina Zec; Hayley L Eames; Erinke van Grinsven; Alison Hudak; Susan Morris; David Ahern; Claudia Monaco; Evgeniy B Eruslanov; Raashid Luqmani; Irina A Udalova
Journal:  JCI Insight       Date:  2020-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.